Ambrosia Biosciences
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
$100MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers
Pitching BVF Partners? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room